查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608967

吸收不良症候群市场：按治疗方法、疾病类型和最终用户分类 - 全球预测 2025-2030

Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

吸收不良症候群市场价值 2023 年为 23.4 亿美元，预计到 2024 年将达到 24.9 亿美元，复合年增长率为 5.66%，到 ​​2030 年将达到 34.5 亿美元。

吸收不良症候群包括多种以肠道无法充分吸收食物中的营养素、维生素和矿物质为特征的疾病。强调解决这种综合症的必要性，因为它可能导致严重的营养缺乏，从而导致对诊断和治疗方案的需求增加。其应用涵盖医疗保健领域，特别是胃肠保健产品、营养食品和医疗诊断。主要最终使用者包括诊断、治疗和管理吸收不良相关病症的医院、诊所和专科医疗中心。吸收不良症候群管理市场主要是由胃肠道疾病盛行率上升、人口老化容易营养不良以及消化健康意识不断增强所推动。诊断工具和治疗方案的技术进步为市场成长提供了有利可图的机会。例如，开发先进的诊断影像技术和非侵入性检测方法以进行早期诊断非常重要。对旨在解决特定缺陷的营养食品的需求激增也支持了成长。然而，市场开拓面临治疗成本上升、新兴国家意识缺乏、医疗基础建设落后等重大挑战。此外，准确诊断这种综合征的复杂性阻碍了及时治疗，从而阻碍了市场动力。这个市场充满了创新和研究的机会，特别是在开发整合饮食管理和药物治疗的综合治疗方法方面。公司还可以从投资更容易获得和更具成本效益的诊断解决方案中受益。随着市场的发展，包括尖端研究、产品开发和患者教育倡议在内的多学科方法将被证明是非常有利的。建议加强与医疗保健提供者的合作，以提高诊断和治疗的可近性，作为开拓潜在细分市场和推动成长的策略倡议。

主要市场统计
基准年[2023] 23.4亿美元
预计年份 [2024] 24.9亿美元
预测年份 [2030] 34.5亿美元
复合年增长率（%） 5.66%

市场动态：快速发展的吸收不良症候群市场的关键市场洞察

吸收不良症候群市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 乳糖不耐症消费者增加
    • 积极的政府措施和针对吸收不良症候群的宣传活动
    • 消化器官系统疾病（例如乳糜泻）增加
  • 市场限制因素
    • 缺乏足够的医疗基础设施
  • 市场机会
    • 增加治疗吸收不良症候群的监管核准和临床试验
    • 新药投资及开发
  • 市场挑战
    • 严格的安全法规和产品召回

波特的五力：驾驭吸收不良症候群市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解吸收不良症候群市场的外部影响

外部宏观环境因素在塑造吸收不良症候群市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解吸收不良症候群市场的竞争状况

对吸收不良综合症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵吸收不良症候群市场供应商的绩效评估

FPNV 定位矩阵是评估吸收不良症候群市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划吸收不良症候群市场的成功之路

吸收不良症候群市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 乳糖不耐症消费者增加
      • 针对吸收不良症候群的有利政府措施和宣传宣传活动
      • 乳糜泻和其他消化系统疾病等致病疾病的发生率增加
    • 抑制因素
      • 缺乏足够的医疗基础设施
    • 机会
      • 吸收不良症候群治疗的监管核准和临床试验增加
      • 新药投资及开发
    • 任务
      • 严格的安全法规和产品召回
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章吸收不良症候群市场的治疗

  • 发炎药
  • 抗生素
  • 止泻药
  • 无麸质饮食
  • 食品补充品
  • 蛋白酶和脂肪酶补充品

第七章吸收不良症候群市场：依疾病类型

  • 囊肿纤维化
  • 乳糖不耐症
  • 浇口

第 8 章吸收不良症候群市场：依最终用户

  • 学术研究所
  • 医院
  • 营养诊所
  • 製药公司

第九章美洲吸收不良症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区吸收不良症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲/中东/非洲吸收不良症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie Inc.
  • Ache Laboratorios Farmaceuticos SA
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Koninklijke Philips NV
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi SA
  • Tillotts Pharma AG
Product Code: MRR-4659C8711BBE

The Malabsorption Syndrome Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 3.45 billion by 2030.

Malabsorption Syndrome encompasses a range of disorders characterized by the intestine's inability to adequately absorb nutrients, vitamins, and minerals from food. The necessity of addressing this syndrome is underscored by its potential to cause severe nutritional deficiencies, leading to an increased demand for diagnostics and treatment options. Its applications span the healthcare sector, particularly focusing on gastrointestinal health products, dietary supplements, and medical diagnostics. Key end-users include hospitals, clinics, and specialized medical centers that diagnose, treat, and manage malabsorption-related conditions. The market for Malabsorption Syndrome management is primarily driven by the rising prevalence of gastrointestinal disorders, aging populations more prone to nutrient deficiencies, and increasing awareness regarding digestive health. Technological advancements in diagnostic tools and treatment options present lucrative opportunities for market growth. For instance, the development of advanced imaging techniques and non-invasive testing methods for early diagnosis is critical. Growth is also supported by a surge in demand for nutritional supplements designed to counter specific deficiencies. However, market expansion faces significant challenges, such as high treatment costs, lack of awareness in developing regions, and inadequate healthcare infrastructure. Furthermore, the complexity of accurately diagnosing the syndrome can impede timely treatment, hindering market momentum. Innovation and research opportunities abound within this market, especially in formulating comprehensive treatment regimens that integrate dietary management with pharmacotherapy. Companies can also benefit from investing in more accessible and cost-effective diagnostic solutions. With the market's evolving nature, a multidisciplinary approach encompassing cutting-edge research, product development, and patient education initiatives could prove highly advantageous. Strengthening collaborations with healthcare providers to enhance diagnosis and treatment accessibility is recommended as a strategic move to tap into potential market segments and foster growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.34 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 5.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malabsorption Syndrome Market

The Malabsorption Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of lactose intolerance consumers
    • Favorable government initiatives and awareness campaigns for malabsorption syndrome
    • Growing incidences of cause disorders such as celiac disease and other digestive diseases
  • Market Restraints
    • Lack of proper healthcare infrastructure
  • Market Opportunities
    • Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
    • Investments and development of novel medicines
  • Market Challenges
    • Stringent safety rules and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Malabsorption Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malabsorption Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malabsorption Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malabsorption Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malabsorption Syndrome Market

A detailed market share analysis in the Malabsorption Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malabsorption Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malabsorption Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malabsorption Syndrome Market

A strategic analysis of the Malabsorption Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malabsorption Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Ache Laboratorios Farmaceuticos S.A., AstraZeneca PLC, Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Koninklijke Philips N.V., Merck & Co., Inc., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., and Tillotts Pharma AG.

Market Segmentation & Coverage

This research report categorizes the Malabsorption Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents, Gluten-Free Diet, Nutritional Supplements, and Protease & Lipase Supplements.
  • Based on Disease Type, market is studied across Cystic Fibrosis, Lactose Intolerance, and Sprue.
  • Based on End-user, market is studied across Academic & Research Institutes, Hospitals, Nutrition Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of lactose intolerance consumers
      • 5.1.1.2. Favorable government initiatives and awareness campaigns for malabsorption syndrome
      • 5.1.1.3. Growing incidences of cause disorders such as celiac disease and other digestive diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of proper healthcare infrastructure
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
      • 5.1.3.2. Investments and development of novel medicines
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent safety rules and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Malabsorption Syndrome Market, by Treatment

  • 6.1. Introduction
  • 6.2. Anti-Inflammatory Drugs
  • 6.3. Antibiotics
  • 6.4. Antidiarrheal Agents
  • 6.5. Gluten-Free Diet
  • 6.6. Nutritional Supplements
  • 6.7. Protease & Lipase Supplements

7. Malabsorption Syndrome Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Cystic Fibrosis
  • 7.3. Lactose Intolerance
  • 7.4. Sprue

8. Malabsorption Syndrome Market, by End-user

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals
  • 8.4. Nutrition Clinics
  • 8.5. Pharmaceutical Companies

9. Americas Malabsorption Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Malabsorption Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Malabsorption Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Ache Laboratorios Farmaceuticos S.A.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. Baxter International Inc.
  • 6. Bayer AG
  • 7. Gilead Sciences, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Koninklijke Philips N.V.
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Perrigo Company PLC
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Tillotts Pharma AG

LIST OF FIGURES

  • FIGURE 1. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. MALABSORPTION SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MALABSORPTION SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIDIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY GLUTEN-FREE DIET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTEASE & LIPASE SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY SPRUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITION CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023